Bridging Translation by Improving Preclinical Study Design in AKI
about
The ten barriers for translation of animal data on AKI to the clinical setting.Bridging translation for acute kidney injury with better preclinical modeling of human diseaseLosartan reduces ensuing chronic kidney disease and mortality after acute kidney injury.Recent early clinical drug development for acute kidney injury.Nanomedicines for renal disease: current status and future applicationsCellular plasticity in kidney injury and repair.Understanding and preventing contrast-induced acute kidney injury.Generalizable Biomarkers in Critical Care: Toward Precision Medicine.Models of Human AKI: Resemblance, Reproducibility, and Return on Investment.An intracellular matrix metalloproteinase-2 isoform induces tubular regulated necrosis: implications for acute kidney injury.Human induced pluripotent stem cell-derived mesenchymal stem cells prevent adriamycin nephropathy in mice.Translating Knowledge Into Therapy for Acute Kidney Injury.Remote effects of acute kidney injury in a porcine model.Determination of renal function and injury using near-infrared fluorimetry in experimental cardiorenal syndrome.Selective Nanoparticle Targeting of the Renal Tubules.Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop.Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications.CRISPR/Cas9 engineering of a KIM-1 reporter human proximal tubule cell line
P2860
Q36357460-FFF83C94-2DD3-48DA-9157-600E1C3C5D1EQ36957116-BB0C5989-73CB-4E24-A549-E4944C8EB379Q37291351-884BC0FB-04B8-46B0-B250-9AD937A80515Q38780169-23BCC599-8C1C-4F67-91F8-400BDA706AB5Q38802375-C4FD1B33-1A22-4940-920D-13611DD445CCQ39021703-F6009782-749E-4F1B-8323-6724AF43131EQ39110308-98097999-C8D0-4176-BBD9-A48A23FC8F19Q40210673-4307AAC1-FAD4-411D-B9A3-80B25B346255Q42631876-878C990D-FFB6-4B38-8F50-EEF5D4C26913Q46076928-497FB0B3-6FFF-4B02-A5E8-3CDB687897FBQ47139383-A9C35AAC-F91A-42B9-B2E3-F97F1BE0B927Q47226520-B183E0A8-02EA-433A-9B9A-EFE0DB3E8F30Q48098176-8404EAAF-F540-4958-885C-00C0334F041AQ48362722-5A5F2FFD-14D7-4EEB-B7A9-F1B6BD62F10BQ48602509-5384625E-C9E4-4383-9411-D6989E649A8EQ52361165-FE97BE91-6768-4A51-9932-0B1993729DCDQ54981618-93155437-66EA-4A9B-9D4E-1D74CA489221Q58691679-1CE6D494-7C9C-4C9B-8EB3-E29EBB843D36
P2860
Bridging Translation by Improving Preclinical Study Design in AKI
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Bridging Translation by Improving Preclinical Study Design in AKI
@ast
Bridging Translation by Improving Preclinical Study Design in AKI
@en
Bridging Translation by Improving Preclinical Study Design in AKI
@nl
type
label
Bridging Translation by Improving Preclinical Study Design in AKI
@ast
Bridging Translation by Improving Preclinical Study Design in AKI
@en
Bridging Translation by Improving Preclinical Study Design in AKI
@nl
prefLabel
Bridging Translation by Improving Preclinical Study Design in AKI
@ast
Bridging Translation by Improving Preclinical Study Design in AKI
@en
Bridging Translation by Improving Preclinical Study Design in AKI
@nl
P2093
P2860
P3181
P356
P1476
Bridging Translation by Improving Preclinical Study Design in AKI
@en
P2093
ASN AKI Advisory Group
Ben D Humphreys
David Askenazi
Frank E Harrell
Girish Mour
Jorge Cerda
Mark D Okusa
Mark de Caestecker
Nick Pullen
Sarah Faubel
P2860
P304
P3181
P356
10.1681/ASN.2015070832
P407
P577
2015-11-04T00:00:00Z